Colombia is preparing to produce cancer drugs within its own territory for the first time. The project, driven entirely with public funding, aims to develop and manufacture a biosimilar monoclonal antibody intended for the treatment of various types of cancer, marking a historic shift in the country’s pharmaceutical policy.
The initiative is part of a strategy to reduce dependence on imported medicines and lower the cost of access to high-priced therapies. Until now, Colombia has relied heavily on the purchase of biotechnological drugs produced abroad, which significantly impacts the health system’s spending and limits the availability of some treatments for patients.
The manufacture of monoclonal antibodies represents one of the greatest technological challenges in the pharmaceutical industry. Unlike traditional chemical drugs, these products require complex biological engineering processes, quality control, and clinical validation.
Each stage, from cell culture to purification of the final product, must meet very strict international standards to guarantee patient safety. This involves the creation of specialized laboratories and production centers equipped with advanced technology.
The success of the project will depend on the ability of public institutions to develop this infrastructure and train scientific teams capable of sustaining production over time.
Colombia to begin producing cancer drugs for the first time
The project envisions the creation of national capabilities to produce a biosimilar monoclonal antibody, one of the most widely used biotechnological therapies in modern oncology. These drugs act specifically on tumor cells and are key in treatments against different types of cancer.
Unlike traditional drugs, monoclonal antibodies are complex biological products obtained from living organisms or cell cultures. Their manufacture requires specialized infrastructure, highly qualified personnel, and very strict control processes, which explains why their production is concentrated in a limited number of countries.
The decision to manufacture these medicines in Colombia responds to a policy aimed at strengthening health sovereignty. The goal is for the country to be able to produce strategic treatments with its own resources, reducing costs and ensuring the supply of therapies considered essential for the health system.
The drug that will be produced is a biosimilar, a version highly comparable to original biological medicines once their patents expire. Although they are not identical copies, they maintain the same level of efficacy, safety, and therapeutic quality.
This type of drug has become a key tool for expanding access to high-cost treatments. Various studies show that biosimilars can generate significant reductions in the price of biotechnological medicines, helping ease financial pressure on health systems.
In the Colombian case, the impact could be especially significant. Monoclonal antibodies are among the most expensive treatments in oncology, and their use has increased in recent years due to their effectiveness in targeted therapies against specific tumors.
The project proposes that the production of the drug be carried out entirely with public investment, meaning that both the scientific development and the industrial infrastructure will be financed by the state. This feature makes it one of the most ambitious initiatives in the recent history of Colombian pharmaceutical policy.
Less dependence on imports
The initiative began to take shape eight years ago and received a formal allocation of resources in 2025. From that point on, the project moved toward a concrete phase with the adaptation of infrastructure included in the modernization of the National Cancer Institute.
That process, which will make it possible to double the manufacturing capacity of hyperimmune sera and launch a small-scale production plant, includes an investment of 1.37 trillion pesos (approximately US$365 million) between 2026 and 2035, aimed at strengthening public or mixed infrastructure and technological development and going beyond cancer.
In this sense, the public initiative will favor vaccine production, in a clear effort to reactivate the technological, scientific, and industrial capacities that Colombia once had in the past but that were lost over the years.
One of the main current problems in Colombia’s pharmaceutical market is the strong dependence on imported medicines, especially in the case of biotechnological products. At present, virtually all biosimilars used in the country are manufactured abroad and later marketed in the national market.
This situation not only increases costs but also exposes the health system to potential supply problems or fluctuations in international prices. Local production could help reduce these risks and ensure greater stability in the supply of treatments.
In addition, the development of scientific and industrial capabilities in the field of biotechnological medicines could open the door to new research and pharmaceutical production projects in the country.
Experts point out that, if the initiative manages to consolidate itself, Colombia could move toward the creation of its own biopharmaceutical industry, capable not only of supplying the domestic market but also of exporting medicines to other Latin American countries.
A disease with a high impact in Colombia
The push to produce cancer drugs also responds to the weight this disease has in the country. In Colombia, more than 117,000 new cancer cases are recorded each year, according to international incidence estimates.
Cancer has also become one of the leading causes of death. Each year, more than 45,000 people in the country die from this disease, reflecting the magnitude of the challenge for the health system. The most frequent types of cancer include breast, prostate, colon, stomach, and lung cancers, which account for a large share of diagnoses and associated mortality.
Against this backdrop, the national production of oncology medicines could become a strategic tool to improve access to treatments and strengthen the health system’s response to one of the most complex and costly diseases to treat.